Professional Chartist. #Follow the money for full, in-depth TA. Traders welcomed to join our Biotech Trading team @ msmoneymoves.com I take it all into consideration; fundamentals, catalysts, fib ratios, eWave, harmonic patterns, trend, and indicators.
Many are saying it but earnings will shine light on DARK places of the future US economy.
Elliott wave -> corrective ascending triangle.
i see what most of you see but am having difficulty with that inner wave iii of my (C) wave. As the rule states, wave 3 can't be the shortest. in fact wave 3 of 3's are usually the longest. The count on this inner 3rd wave's,...
EYPT chart is building up for another run. Potential catalyst before year end with an sNDA for Short Duration Yutiq. accumulation has been slow and steady indicating EYPT oversold conditions.
weekly chart --> Harmonic Gartley (bounced off significant support level) and been in uptrend since.
Symmetrical Triangle/ Breakout setup has been known...
Biotech buyouts have been very strong, especially with Gene therapy stocks as of late.
Bounced off Lower end of channel
bounced off 1.618 fib extension along with important reversal leg of Elliott Wave Theory.
if price holds inside the lower end of the channel there is a potential move back up and test the gap.
looking for nice $0.40+ swing...
BLCM has been in continuous long-term downtrend since IPO. Stock price has been showing signs of a bo...
Click here to read the rest of my analysis on BLCM.
Disclosure: I am long BLCM. This is not a recommendation to buy/sell as I am NOT a financial advisor. Please do your homework before investing.
MRKR showing signs of life after testing a key Fibonacci level of support.
CCI moved positive (inferring a nice loading zone)
MS Signal is showing "Over-Sold" conditions
Key *Support needs to hold $3.80
Key *Resistance at $4.53 then $5.29 (highlighted in green shaded area)
Disclosure: I do not own MRKR. I may buy/ sell within...
Friday, October 11, 2019
ADVM is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,
ADVM is set to present additional clinical data for the first cohort of patients (n=6) in the OPTIC phase 1 clinical trial of ADVM-022, intra-vitreal injection gene therapy in wet age-related macular degeneration (wet AMD) at the...
As the month of October begins and broader markets sold off, Biotech sectors are still negative/ flat for the year. Market headlines from high prescription drug prices and lawsuits regarding the opioid epidemic have plagued some of the IBB's largest holdings; which have held biotech ETF's down while the S&P reached all time highs.
This year has been full of positive catalysts for RGNX. As RGNX continues to build out their clinical pipeline, data catalyst from upcoming phase 2a report on their Wet-AMD gene therapy product could send the stock roaring higher. RGNX is set to report data Oct. 13, 2019 and the companies technical setup is quite nice. The Wet-AMD market is a lucrative opportunity...
Conformis Inc. (Nasdaq: CFMS) is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture & sell patient specific joint replacement implants. The implants are designed to fit each patient's unique anatomy.
CFMS stated in their previous ER (July 31, 2019), the company was updating their 2019 outlook...
Conformis, Inc. (NASDAQ: CFMS), is a medical device/ technology company that uses its proprietary iFit 'Image-to-Implant' technology platform to develop, manufacture and sell patient specific joint replacement implants that are designed to fit each patient's unique anatomy.
Bullish Gartley pattern (786 retracement)
Leap is looking to make another leap. Harmonic shark patterns leave more room for volatility trades and make for high reward scenario's when traded correctly.
As of today (09-04-2019), 84,220 of the 261,828 shares traded where short. This is equivalent to a sizable 32.17% short percent.
The technical's are now aligning with some key dates with a potential short...
ADMA FAILED TO BREAK RESISTANCE. THIS ALSO HAPPENS TO BE A BEARISH HARMONIC GARTLEY PATTERN WITH DECLINING STOCHASTIC, RSI AND VOLUME AT THE END OF A KEY FIBONACCI CYCLE.
PREVIOUS REPEATING STAIRWAY PATTERN SUGGEST'S PULLBACK COMING (SYMMETRICAL) . LOOK FOR APPROXIMATELY 618 RETRACEMENT FROM RECENT TOP (RESISTANCE).
DISCLOSURE : I AM LONG ADMA, I MAY BUY/...
Final Data from Robarts study coming September, in Spain. To learn more about TAEUS, click here .
Company ran by ex-GE executives. TAM is in the Billions of Dollars $$. Low float.
Recently broke long-term down trend. Daily, Weekly, Monthly charts #BULLISH. Fibonacci convergence at 618 fib (projection) into September time frame.
Follow me on twitter and...
Neckline (outlined in blue) for inverse Head and shoulders.
Harmonic Cypher pattern @786 retracement, where ADMA bounced.
RSI moving up with trend, showing strong accumulation (Bulls in control)
Highlighted in the blue box's is a pattern that I've been watching for awhile now. As you can see, they are very similar and just so happens that today's close was pushing...
Almost exactly one-year ago NDRA received this same form 8-K "Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing." *Shortly after recieving this notice, NDRA's Price shot up dramatically.
In September, ENDRA Life Sciences is planning to present the final results of the #Robarts study in conjunction with the...
SGEN has beat biotech averages significantly the past few months and has come to meet my $80 pt which also happens to make a bearish harmonic butterfly pattern. This could have a little more upside as it tests $80-81 but risk/reward would suggest a potential double top that can take this down quite a bit in a short amount of time. If I was short I would be looking...
Bearish head and shoulders setup. Most likely no sales. I will look to add after retracement. Potential AB=BC harmonic correction.
Disclosure: I do not own shares of OCUL. This is not a note to buy or sell. please do your hw before investing.